E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Locally Advanced or Metastatic Non Small Cell Lung Cancer stage IIIb - IV |
|
E.1.1.1 | Medical condition in easily understood language |
Advanced or Metastatic Non Small Cell Lung Cancer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy in terms of Progression-Free Survival (PFS) for each comparison of selumetinib in combination with docetaxel, compared to placebo in combination with docetaxel |
|
E.2.2 | Secondary objectives of the trial |
To assess the efficacy of each comparison of selumetinib in combination with docetaxel, compared to placebo in combination with docetaxel, in terms of: OS, ORR, DoR, Change in tumour size at week 6
To assess the safety and tolerability profile for each treatment group
To explore whether KRAS mutation status is predictive of efficacy of selumetinib in combination with docetaxel, compared with docetaxel alone
To assess the effect on NSCLC symptoms for each comparison
To assess the effect on health-related quality of life (HRQoL) for each comparison
To investigate the pharmacokinetics (PK) of selumetinib and N-desmethyl selumetinib when administered in combination with docetaxel |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Provision of signed, written and dated informed consent prior to any study specific procedures
Male or female, aged 18 years or older
Histological or cytological confirmation of locally advanced or metastatic NSCLC (IIIB-IV)
Prospective confirmation of KRAS mutation negative status as determined using the cobas® KRAS Mutation Test (Roche Molecular Systems) via an AZ approved laboratory
Failure of 1st line anti-cancer therapy due to radiological documentation of disease progression in advanced disease or subsequent relapse of disease following 1st line therapy
|
|
E.4 | Principal exclusion criteria |
Mixed small cell and non-small cell lung cancer histology
Received >1 prior anti-cancer drug regimen for advanced or metastatic NSCLC. Patients who develop disease progression while on switch maintenance therapy (maintenance using an agent not in the first-line regimen) will not be eligible.
Having received an investigational drug within 30 days of first dose of study treatment or within five half-lives of the compound, or have not recovered from side effects of an investigational drug.
Receiving or have received systemic anti-cancer therapy within 30 days prior to starting study treatment.
Other concomitant anti-cancer therapy agents except steroids
Prior treatment with a MEK inhibitor or any docetaxel-containing regimen (prior treatment with paclitaxel is acceptable)
The last radiation therapy within 4 weeks prior to starting study treatment, or limited field of radiation for palliation within 7 days of the first dose of study treatment |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To assess the efficacy in terms of Progression-Free Survival (PFS) for each comparison of selumetinib in combination with docetaxel, compared to placebo in combination with docetaxel |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Patient's disease status is measured at baseline, every 6 weeks after start of treatment until objective disease progression or a discontinuation criterion is met |
|
E.5.2 | Secondary end point(s) |
To assess the efficacy of each comparison of selumetinib in combination with docetaxel, compared to placebo in combination with docetaxel, in terms of: Overall Survival, Objective Response Rate, Duration of Response, Change in tumour size at week 6
To assess the safety and tolerability profile for each treatment group
To explore whether KRAS mutation status is predictive of efficacy of selumetinib in combination with docetaxel, compared with docetaxel alone
To assess the effect on NSCLC symptoms for each comparison
To assess the effect on health-related quality of life (HRQoL) for each comparison
To investigate the pharmacokinetics (PK) of selumetinib and N-desmethyl selumetinib when administered in combination with docetaxel |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Patient´s disease status is measured at baseline, every 6 weeks after start of treatment until objective disease progression or a discontinuation criterion is met.
Measured from consent, throughout the study and until a study discontinuation criterion is met
KRAS mutation status will be confirmed prior to or as soon as possible after randomisation
LCSS are to be completed from randomisation visit, every scheduled visit thereafter until 30 days post treatment discontinuation
LCSS are to be completed from randomisation visit, every scheduled visit thereafter until 30 days post treatment discontinuation, the Short Form Health Survey - 36 Items (V2) has to be completed at randomisation visit and at week 3, week 12 and at treatment discontinuation
pK samples taken on day 22 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 46 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Brazil |
Bulgaria |
France |
Germany |
Hungary |
Netherlands |
Poland |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 17 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 17 |